RA Capital Management, L.P. 13D and 13G filings for Cytek Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:29 pm Sale |
2024-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 0 0.000% |
-6,809,404 (Position Closed) |
Filing |
| 2024-02-22 7:07 pm Unchanged |
2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 6,809,404 5.200% |
0 (Unchanged) |
Filing |
| 2023-09-19 5:25 pm Sale |
2023-09-15 | 13D | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 6,809,404 4.990% |
-6,329,923 (-48.18%) |
Filing |
| 2022-03-14 5:04 pm Purchase |
2022-03-10 | 13D | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 13,139,327 9.800% |
2,057,164 (+18.56%) |
Filing |
| 2022-02-28 5:29 pm Purchase |
2022-02-28 | 13D | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 11,082,163 8.300% |
1,475,135 (+15.35%) |
Filing |
| 2021-08-06 4:30 pm Purchase |
2021-07-27 | 13D | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 9,607,028 7.200% |
9,607,028 (New Position) |
Filing |